PharmaDeals Research Reveals Early Signs of Recovery in Pharma Industry Deal Making

OXFORD, England, February 22, 2011 - PharmaDeals(R) research has revealed that the early stages of recovery
are now evident within pharmaceutical deal-making activity. The overall
number of deals in 2010 grew relative to 2009, and whilst collaborative R&D
deals continue to decline in numbers and value, licensing activity is on the
increase.

Fintan Walton, PhD, Chief Executive of PharmaVentures, says, "The current
deal-making landscape in the life science industry is fascinating, and
reflects the forces for change operating worldwide. For example, research
based on our PharmaDeals database shows that deal structures for M&A
transactions are becoming more and more complex, yet values are declining. In
order to benefit, small and large companies alike will require increasing
levels of sophistication in terms of their deal-making ability." The results
were recently presented by Dr Walton at the Sachs 4th Annual European Life
Sciences CEO Forum for Partnering & Investing held in Zurich, and through
analysis published by the journal PharmaDeals Review.

Anne Vindenes Allen, Executive Director for PharmaDeals, explains, "It is
vital for industry deal makers to keep pace with these developments and use
best available business intelligence. Analysis of our PharmaDeals data shows
the variation in values within different deals types, as well as within
development stages and therapy areas. We always go the extra mile to source
and classify critical information to help our clients distil critical
intelligence."

Fintan Walton concludes, "Our consultants help bring companies together
to further their mutual aims - it's all about teasing out the win-win
scenarios. Without an appreciation for what others are doing in the industry,
that is pretty much an impossible task."

PharmaDeals v4 is the world's first online, multimedia, dedicated to the
pharmaceutical and biotechnology industry, deals intelligence resource. Data
for the report, 'Deal Making in 2010' - an annual review - was obtained from
analysis of the PharmaDeals v4 Agreements database.

Secure a copy of the PharmaDeals Review article, entitled 'Deal Making in
2010' here www.pharmadeals.net/download_deal_making_2010

Journal available at www.pharmadealsreview.com

PharmaVentures Limited (www.pharmaventures.com) is a leading
international corporate advisory firm supporting its clients' growth
ambitions in the health care industry. It has considerable experience and
expertise in the field of tangible and intangible transactions, providing
advice at both a strategic level, as well as acting as advisor and broker at
an implementation level. Its transactional experience includes licensing,
joint ventures, mergers, acquisitions and divestments. Its clients are
worldwide, including Europe, the USA and AsiaPacific. Clients range from
start-ups to global pharmaceutical corporations, diversified industrial
corporations, investment houses and government bodies. PharmaVentures
produces the highly popular PharmaDeals(R) (www.pharmadeals.net) range
of intelligence products including analysis tools and reports. Its
subsidiary, PharmaTelevision Limited, offers the world's first dedicated
online pharmaceutical television channel PharmaTelevision(R)
(www.pharmatelevision.com).

Now in its 19th year, PharmaVentures is based in Oxford, UK, and employs
over 30 people.

PharmaDeals(R) and PharmaTelevision(R) are registered Trade Marks of
PharmaVentures Ltd.

Information about PharmaDeals v4 Agreements is available at
www.pharmadeals.net/agreements , www.pharmadeals.net/ ,
or contact us today.

    For further information:

    Anne Vindenes Allen
    Executive Director, PharmaDeals
    +44(0)1865-332700
    anne.allen@pharmaventures.com

For further information: Anne Vindenes Allen, Executive Director, +44(0)1865-332700, anne.allen at pharmaventures.com